Cleared Traditional

K895995 - RHEUMELISA ASSAY FOR SS-B/LA AUTOANTIBODIES

K895995 is an FDA 510(k) clearance for RHEUMELISA ASSAY FOR SS-B/LA AUTOANTIBODIES, manufactured by Lipogen, Inc.. The device is a Class 2 Immunology device with product code LJM cleared through the Traditional 510(k) pathway after a 14-day FDA review.

K895995 · Lipogen, Inc. · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Oct 1989
Decision
14d
Days
Class 2
Risk

K895995 is an FDA 510(k) clearance for the RHEUMELISA ASSAY FOR SS-B/LA AUTOANTIBODIES. Classified as Antinuclear Antibody (enzyme-labeled), Antigen, Controls (product code LJM), Class II - Special Controls.

Submitted by Lipogen, Inc. (Knoxville, US). The FDA issued a Cleared decision on October 27, 1989 after a review of 14 days - a notably fast clearance cycle.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5100 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Lipogen, Inc. devices

FDA 510(k) Submission Details - K895995

510(k) Number K895995 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received October 13, 1989
Decision Date October 27, 1989
Days to Decision 14 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
91d faster than avg
Panel avg: 105d · This submission: 14d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

LJM Device Classification - Class 2, Special Controls

Product Code LJM Antinuclear Antibody (enzyme-labeled), Antigen, Controls
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5100
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - LJM Antinuclear Antibody (enzyme-labeled), Antigen, Controls

All 80
Devices cleared under the same product code (LJM) and FDA review panel - the closest regulatory comparables to K895995.
ANTI-SCI-70 MICROASSAY
K902915 · Diamedix Corp. · Sep 1990
IMMUNODOT AUTOIMMUNITY SCREENING PANEL 2
K900072 · General Biometrics, Inc. · Jan 1990
IMMUNODOT AUTOIMMUNE SCREENING PANEL 1
K896347 · General Biometrics, Inc. · Dec 1989
ANTI-SM MICROASSAY
K894894 · Diamedix Corp. · Aug 1989
DNA STAT TEST KIT
K843904 · Whittaker Bioproducts, Inc. · Nov 1984
AMIZYME-ANA TEST KIT
K842532 · Amico Lab, Inc. · Sep 1984